BUY
TP: Rs 1,780 | ⮝ 18%

SYRMA SGS | EMS | 03 November 2026

Growth broadens; guidance revised upwards

- **Revenue/EBITDA/Adj. PAT grew 74%/68%/83% YoY; EBITDA margin fell 30bps to 9.7% on component cost push**
- **Automotive (+91%) and Industrials (+86%) drove growth; Healthcare flat QoQ, Consumer share down to 29%**
- **Raise estimates; assign 45x to Sep'28E EPS to arrive at Sep'27 TP of Rs 1,780; upgrade to BUY**

Amey Tupe
Research Associate

Vineet Shanker
Research Analyst
research@bobcaps.in

Cost push compresses gross margin: Revenue rose 74% YoY (25% QoQ) to Rs 19.9bn, 26% ahead of our estimate. EBITDA grew 68% YoY to Rs 1.9bn, a 27% beat. Gross margin contracted 274bps YoY to 21.1% on component cost push, per management. Lower employee (39bps) and other expenses (200bps) limited the EBITDA margin decline to 35bps YoY (46bps QoQ). At 9.7%, margin trails the 10.5-11.0% FY27 guidance. Adj. PAT rose 83% YoY to Rs 1.2bn as D&A (+4%) and interest (+21%) lagged EBITDA and the tax rate eased 105bps. This absorbed a threefold rise in minority interest to Rs 69mn.

Automotive and Industrials drive the mix shift: Automotive (Rs 5.2bn, +91% YoY, +31% QoQ) and Industrials (Rs 4.9bn, +86% YoY, +31% QoQ) formed 51% of revenue, up from 47% in Q2FY26. IT & Railways rose 69% YoY and 82% QoQ, lifting its share to 14% from 9% in Q1FY27. Consumer, a lower-margin vertical, grew 57% YoY but only 7% QoQ; its share fell to 29% from 32% a year ago (34% in Q1FY27). Healthcare grew 61% YoY but was flat QoQ. Exports rose 91% YoY to 26% of revenue, and ODM formed 16%.

Order book grows 10% QoQ; working capital eases: The order book rose 10% QoQ to Rs 74.2bn in Sep'26, of which Rs 12.0bn falls beyond 12 months. Automotive formed ~30%, with Consumer and Industrials at ~24-25% each. Net working capital improved to 63 days from 71 in Q1FY27, as inventory rose ~50% since Mar'26 against ~70% revenue growth. Net cash doubled QoQ to Rs 2.6bn.

PCB on track for Apr'27 trial runs: Equipment installation and commissioning at the PCB plant are due by Mar'27, with trial runs from Apr'27. Volume production should follow by Sep'27, after customer approvals. PCB capex was ~Rs 1.4bn in Q2FY27 (~Rs 500mn in Q1), taking cumulative spend above Rs 2.0bn.

Raise estimates; upgrade to BUY: We raise FY27E/FY28E/FY29E revenue by 5%/4%/5% and EPS by 2%/6%/16%. FY26-29E revenue/EBITDA/PAT CAGR is 36%/38%/41%. At an unchanged 45x Sep'28E EPS, our Sep'27 TP rises to Rs 1,780 (from Rs 1,460), 18% upside. We upgrade to BUY.

Key changes

Target	Rating
▲	▲

Ticker/Price	SYRMA IN/Rs 1,512
Market cap	US$ 2.8bn
Free float	53%
3M ADV	US$ 31.9mn
52wk high/low	Rs 1,823/Rs 635
Promoter/FPI/DII	47%/5%/9%


Source: NSE | Price as of 2 Nov 2026

Key financials

Y/E 31 Mar	FY26A	FY27E	FY28E
Total revenue (Rs mn)	48,191	70,039	94,123
EBITDA (Rs mn)	5,445	6,663	9,972
Adj. net profit (Rs mn)	3,224	4,007	6,119
Adj. EPS (Rs)	16.7	20.8	31.8
Adj. ROAE (%)	14.0	13.1	17.4
Adj. P/E (x)	90.4	72.7	47.6
EV/EBITDA (x)	49.1	40.1	26.8
Adj. EPS growth (%)	73.2	24.3	52.7

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE

Fig 1 – Quarterly & H1FY27 financial snapshot

Particulars (Rs mn)	Q2FY27	Q2FY26	YoY (%)	Q1FY27	QoQ (%)	H1FY27	H1FY26	YoY (%)	Q2FY27E	Var (%)
Revenue	19,897	11,459	74	15,886	25	35,783	20,899	71	15,779	26
EBITDA	1,933	1,152	68	1,616	20	3,549	2,019	76	1,517	27
EBITDA Margin (%)	9.7	10.1	(30bps)	10.2	(50bps)	9.9	9.7	30bps	9.6	10bps
Depreciation	227	218		225		452	424			
Interest	153	126		133		286	276			
Other Income	99	87		151		249	248			
PBT	1,652	895	85	1,408	17	3,060	1,567	95		
Tax	410	232		351		761	404			
Adjusted PAT	1,173	641	83	1,001	17	2,173	1,138	91	940	25
Exceptional item	-	-		-		-	-			
Reported PAT	1,173	641	83	1,001	17	2,173	1,138	91	940	25
Adj. PATM (%)	5.9	5.6	30bps	6.3	(40bps)	6.1	5.4	60bps	6.0	(7bps)
EPS (Rs)	6.4	3.4	87	5.5	18	12.0	6.6	82	5.3	21

Source: Company, BOBCAPS Research

Fig 2 – Segmental performance

Particulars (Rs mn)	Q2FY27	Q2FY26	YoY (%)	Q1FY27	QoQ (%)	H1FY27	H1FY26	YoY (%)
Segment Revenue								
Automotive	5,169	2,710	91	3,949	31	9,118	4,925	85
Consumer	5,727	3,656	57	5,328	7	11,055	6,834	62
Healthcare	1,340	834	61	1,345	0	2,685	1,508	78
Industrials	4,935	2,649	86	3,766	31	8,701	5,522	58
IT and Railways	2,727	1,610	69	1,497	82	4,224	2,110	100


Source: Company, BOBCAPS Research

Earnings Call Highlights

- **Revenue guidance raised to 40-45% growth:** Management raised FY27 revenue growth guidance to 40-45% from ~35%, implying ~Rs 70bn of revenue, and quantified the upgrade it had deferred at Q1. It expects FY28 revenue above US$1bn and 30-35% annual growth over three to five years. On our arithmetic, the guide implies H2FY27 growth of 16-25% YoY, against 71% in H1.
- **Margin guidance trimmed to 10.0-10.5%:** Management lowered FY27 EBITDA margin guidance to 10.0-10.5%, below the Q1 range, after an H1 margin of 9.9%. It stated that cost push is passed through but earns no value addition, diluting margin. It expects 10.5-11.0%, possibly above 11%, in FY28 as PCB and other accretive projects start. On our arithmetic, the FY27 range needs an H2 margin of 10.1-11.2%.
- **H2 slowdown reflects front-loading and supply:** Management attributed the slower implied H2 growth to orders front-loaded into H1, including over Rs 11bn of Consumer revenue, and to component shortages rather than demand. It expects Consumer to taper and Industrials to grow faster in H2. It expects supply constraints to ease only in Apr-Jun'27.
- **Cost push contributed 3-5% of revenue:** Management estimated that ~5% cost push raised Q2FY27 material cost by ~3%, partly due to mix. It attributed ~Rs 0.5–0.7bn of Q2 revenue to pass-through pricing and the balance to volume. Export contracts are fixed price; domestic contracts carry a forex pass-through.
- **Export estimates lifted above Rs 17bn:** Management now expects FY27 exports above Rs 17bn, from Rs 15-16bn at the start of the year, on a FY26 base of Rs 12bn. This implies over 40% growth, versus 30-40% guided in Q1. It expects ~Rs 20bn in FY28. Industrials, MedTech and Automotive form the bulk of exports, and new global customers drive the growth.
- **ODM share stalls despite 117% growth:** H1FY27 ODM revenue rose 117% YoY to Rs 5.9bn, but its share held near Q1's ~17% as non-ODM revenue also grew. Management expects FY27 ODM revenue of Rs 10–11bn, versus Rs 8.25bn in FY26, led by healthcare, defence, power electronics, RFID and magnetics. It did not restate the ~25% long-term share target.
- **US$250mn framework deal ramps from FY28:** A ~US$250mn framework agreement for industrial, power management and data-centre products has completed early production runs. Management expects annualised revenue of Rs 5-6bn to start, with full impact from FY28. SYRMA onboarded ~18 customers in H1FY27, versus 32 in FY26.
- **Customer concentration remains contained:** The top 5, 10 and 20 customers formed 38%, 50% and 66% of H1FY27 revenue. The largest customer accounts for 12–14% of revenue; all others are below 10%.
- **Order book excludes forecasts and framework contracts:** Rolling forecasts and framework contracts enter the order book only as purchase orders, usually at the start of a quarter. Management stated order growth can therefore trail revenue growth. Supply constraints have led some Automotive customers to order beyond 12 months.


- **Strategic inventory to stay until supply eases:** Inventory of Rs 15.7bn equalled 71 days, unchanged from Mar'26, including strategic stock of long-lead components. Management will hold this until supply eases, possibly beyond FY27, and targets annual NWC of 60-65 days.
- **PCB to add Rs 2-3bn of revenue in FY28:** Management expects PCB revenue of Rs 2–3bn in FY28 from six to seven months of production. FY29 revenue should reach Rs 9-10bn at 70-80% utilisation, or Rs 12.0-13.5bn at full capacity. Steady-state EBITDA margin is guided at 15-18% excluding PLI and 17-20% including it, with no early PAT loss expected.
- **PCB investment rises to Rs 8–9bn by Mar'28:** Total PCB investment will be Rs 8-9bn by Mar'28, including Rs 4.0-4.5bn by Mar'27, implying ~Rs 2bn more in H2FY27. Management expects to recover ~Rs 2bn of state capital subsidy and targets project returns above 30-35% including incentives. Ex-PCB capex is Rs 1.0-1.5bn a year for two years.
- **ECMS pipeline adds camera modules and laminates:** SYRMA has applied for five to six projects under the Electronics Component Manufacturing Scheme (ECMS). Automotive camera modules should start production by end-FY27, with Rs 0.5–1.0bn initial revenue on ~Rs 300mn capex. Copper clad laminate and HDI/flex PCBs are planned for FY29, after the PCB plant stabilises.
- **JVs to add Rs 2.5-3.5bn in FY28:** The Elemaster JV commissioned its Bengaluru plant in Sep'26 and expects Rs 1.5-2.0bn revenue in FY28 after certification. The KAGA Electronics JV needs IATF approval and expects Rs 1.0-1.5bn in FY28. Management sees each partnership reaching Rs 5–8bn within five years.
- **Elcome and Syrma Johari scale; minority interest rises:** Elcome contributed Rs 1.35bn in H1FY27 and targets Rs 3.0–3.5bn in FY27. Syrma Johari MedTech contributed Rs 1.4bn and targets ~Rs 3bn, up 45-50%, and has commissioned a medical-grade plastics facility at Jodhpur. Minority interest, mainly from these two, should reach Rs 300-450mn in FY27.
- **Railways and Healthcare carry higher margins:** Management placed Railways margins at or above Industrials and described Healthcare as higher margin. IT is low margin, comparable to Consumer, but needs little working capital and earns no PLI. Railways grew 45% YoY in H1FY27.

Fig 3 – Revenue growth




Source: Company, BOBCAPS Research

Fig 4 – EBITDA growth




Source: Company, BOBCAPS Research

Fig 5 – PAT growth




Source: Company, BOBCAPS Research

Fig 6 – Working capital cycle trend




Source: Company, BOBCAPS Research

Fig 7 – Liquidity profile




Source: Company, BOBCAPS Research

Fig 8 – Automobiles growth trend




Source: Company, BOBCAPS Research

Fig 9 – Consumer growth trend




Source: Company, BOBCAPS Research

Fig 10 – Healthcare growth trend




Source: Company, BOBCAPS Research

Fig 11 – Industrials growth trend



Source: Company, BOBCAPS Research

Fig 12 – IT and Railway growth trend




Source: Company, BOBCAPS Research

Valuation methodology

We raise FY27E/FY28E/FY29E revenue by 5%/4%/5% on upgraded guidance, and EBITDA by 1%/5%/14% (margin (33bps)/+3bps/+91bps), reflecting cost push near term and PCB from FY29E. PAT/EPS rise 2%/6%/16%. We estimate revenue/EBITDA/PAT CAGR of 36%/38%/41% over FY26-29E on the adjusted FY26 base. An unchanged 45x P/E on Sep'28E EPS gives a Sep'27 TP of Rs 1,780 (18% upside). Upgrade to BUY.

Fig 13 – SYRMA 1YF P/E band chart



Source: Company, BOBCAPS Research

Fig 14 – Revised estimates

Particulars (Rs mn)	New			Old			Change (%)		
	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E
Revenue	70,039	94,123	1,22,521	66,791	90,152	1,16,978	5	4	5
EBITDA	6,663	9,972	14,322	6,575	9,526	12,612	1	5	14
EBITDA Margin (%)	9.5	10.6	11.7	9.8	10.6	10.8	(33bps)	3bps	91bps
PAT	4,007	6,119	9,082	3,941	5,785	7,803	2	6	16
EPS	21	32	47	20	30	41	2	6	16

Source: BOBCAPS Research

Financials

Income Statement

Y/E 31 Mar (Rs mn)	FY25A	FY26A	FY27E	FY28E	FY29E
Total revenue	**37,867**	**48,191**	**70,039**	**94,123**	**1,22,521**
EBITDA	3,233	5,445	6,663	9,972	14,322
Depreciation	751	841	943	1,410	1,690
EBIT	2,482	4,604	5,720	8,562	12,632
Net interest inc./(exp.)	(585)	(483)	(600)	(540)	(360)
Other inc./(exp.)	494	378	650	650	500
Exceptional items	0	0	0	0	0
EBT	2,392	4,499	5,770	8,672	12,772
Income taxes	526	996	1,452	2,183	3,215
Extraordinary items	21	46	0	0	0
Min. int./Inc. from assoc.	0	0	25	50	50
Reported net profit	**1,699**	**3,178**	**4,007**	**6,119**	**9,082**
Adjustments	21	46	0	0	0
Adjusted net profit	**1,720**	**3,224**	**4,007**	**6,119**	**9,082**

Balance Sheet

Y/E 31 Mar (Rs mn)	FY25A	FY26A	FY27E	FY28E	FY29E
Accounts payables	15,744	19,586	28,399	38,165	49,680
Other current liabilities	812	1,601	1,701	1,801	1,901
Provisions	0	0	0	0	0
Debt funds	6,646	3,999	4,999	4,499	2,999
Other liabilities	1,345	3,893	3,893	3,893	3,893
Equity capital	1,780	1,926	1,926	1,926	1,926
Reserves & surplus	15,719	26,696	30,413	36,244	45,036
Shareholders' fund	17,500	28,622	32,340	38,170	46,963
Total liab. and equities	**42,047**	**57,700**	**71,331**	**86,527**	**1,05,435**
Cash and cash eq.	3,942	2,988	5,510	3,361	3,020
Accounts receivables	14,775	18,408	27,248	36,102	46,994
Inventories	8,219	10,616	16,310	21,919	28,532
Other current assets	2,474	9,485	2,303	3,094	4,028
Investments	180	485	485	485	485
Net fixed assets	8,030	9,870	13,627	15,717	16,528
CWIP	719	675	675	675	675
Intangible assets	3,460	4,754	4,754	4,754	4,754
Deferred tax assets, net	0	0	0	0	0
Other assets	248	418	418	418	418
Total assets	**42,047**	**57,700**	**71,331**	**86,527**	**1,05,435**

Cash Flows

Y/E 31 Mar (Rs mn)	FY25A	FY26A	FY27E	FY28E	FY29E
Cash flow from operations	**1,765**	**2,896**	**6,511**	**2,140**	**3,947**
Capital expenditures	(2,452)	(1,753)	(4,700)	(3,500)	(2,500)
Change in investments	626	(2,644)	0	0	0
Other investing cash flows	774	(3,023)	0	0	0
Cash flow from investing	**(1,052)**	**(7,420)**	**(4,700)**	**(3,500)**	**(2,500)**
Equities issued/Others	(125)	9,651	0	0	0
Debt raised/repaid	330	(3,266)	1,000	(500)	(1,500)
Interest expenses	0	0	0	0	0
Dividends paid	(912)	(807)	(289)	(289)	(289)
Other financing cash flows	0	0	0	0	0
Cash flow from financing	**(707)**	**5,579**	**711**	**(789)**	**(1,789)**
Chg in cash & cash eq.	**6**	**1,055**	**2,522**	**(2,149)**	**(342)**
Closing cash & cash eq.	**3,942**	**2,988**	**5,510**	**3,361**	**3,020**

Per Share

Y/E 31 Mar (Rs)	FY25A	FY26A	FY27E	FY28E	FY29E
Reported EPS	9.5	16.5	20.8	31.8	47.1
Adjusted EPS	9.7	16.7	20.8	31.8	47.1
Dividend per share	1.5	1.5	1.5	1.5	1.5
Book value per share	98.3	148.6	167.9	198.2	243.8

Valuations Ratios

Y/E 31 Mar (x)	FY25A	FY26A	FY27E	FY28E	FY29E
EV/Sales	7.1	5.5	3.8	2.8	2.2
EV/EBITDA	82.7	49.1	40.1	26.8	18.7
Adjusted P/E	156.5	90.4	72.7	47.6	32.1
P/BV	15.4	10.2	9.0	7.6	6.2

DuPont Analysis

Y/E 31 Mar (%)	FY25A	FY26A	FY27E	FY28E	FY29E
Tax burden (Net profit/PBT)	71.9	71.6	69.4	70.6	71.1
Interest burden (PBT/EBIT)	96.4	97.7	100.9	101.3	101.1
EBIT margin (EBIT/Revenue)	6.6	9.6	8.2	9.1	10.3
Asset turnover (Rev./Avg TA)	4.7	4.9	5.1	6.0	7.4
Leverage (Avg TA/Avg Equity)	0.5	0.4	0.4	0.4	0.4
Adjusted ROAE	10.2	14.0	13.1	17.4	21.3

Ratio Analysis

Y/E 31 Mar	FY25A	FY26A	FY27E	FY28E	FY29E
YoY growth (%)					
Revenue	20.1	27.3	45.3	34.4	30.2
EBITDA	59.9	68.4	22.4	49.7	43.6
Adjusted EPS	57.3	73.2	24.3	52.7	48.4
Profitability & Return ratios (%)					
EBITDA margin	8.5	11.3	9.5	10.6	11.7
EBIT margin	6.6	9.6	8.2	9.1	10.3
Adjusted profit margin	4.5	6.7	5.7	6.5	7.4
Adjusted ROAE	10.2	14.0	13.1	17.4	21.3
ROCE	9.1	12.1	12.0	15.5	19.3
Working capital days (days)					
Receivables	142	139	142	140	140
Inventory	79	80	85	85	85
Payables	152	148	148	148	148
Ratios (x)					
Gross asset turnover	4.1	4.2	4.6	4.9	5.5
Current ratio	1.3	1.7	1.5	1.5	1.5
Net interest coverage ratio	4.2	9.5	9.5	15.9	35.1
Adjusted debt/equity	0.4	0.1	0.2	0.1	0.1

Source: Company, BOBCAPS Research | Note: TA = Total Assets

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**
Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**
SEBI Research Analyst Registration No: **INH000000040 (Perpetual)**
SEBI Stock Broker Registration No: **INZ000159332**
SEBI Depository Participant Registration No: **IN-DP-728-2022**
SEBI Merchant Banker Registration No: **INM000009926**
Phone: +91-22-61389300
Name of the Compliance Officer: Mr. Sameer Khobrekar
Email ID: Compliance@bobcaps.in; Phone no.: +91-22-61389358
For any queries or grievances, you may contact the Grievance Officer.
Name of the Grievance Officer: Mr. Nilesh Mehta
Email ID: head-customercare@bobcaps.in; Phone no: 92288 60945

Brand Name: **BOBCAPS**
Website: **https://www.bobcaps.in/**
CIN: **U65999MH1996GOI098009**

Logo:

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%


HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): SYRMA SGS (SYRMA IN)



B – Buy, H – Hold, S – Sell, A – Add, R – Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("**MSL**") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as **"MAYBANK**"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.